Contact Lens-Wearing Dry Eye Subjects Who Are Treated With Acoltremon 0.003%

Dry Eye Disease is a multifaceted condition which has symptoms such as eye dryness, burning, and stinging sensation in the eyes. As well as clinical diagnosis such as a decreased ability to create tear film. Despite improvements in Contact Lenses (CL) DED still is responsible for a large percentage of CL dropouts due to discomfort. Thus, the purpose of this study is to determine if acoltremon 0.003% can improve the frequency and severity of DED symptoms in CL wearers.

Inclusion Criteria: * • Adult subjects who are ≥18 years of age. * Best corrected CL visual acuity of 0.1 Logarithm of the Minimum Angle of Resolution (logMAR) or better in both eyes (Snellen equivalent 20/25). * Willing to wear a new pair of CLs to the baseline study visit. * Daily, soft, frequent replacement CL wearer (daily disposable, bi-weekly, or monthly CLs). * An Eye Dryness VAS score of ≥40. * CLDEQ-8 scores (CLDEQ-8 scores ≥12). * A score of \>7 dots on the Lexitas NEI staining scale (grade 1 in a single sector on the 5-sector scale). * Habitual wearers of soft CLs for a minimum of 5 days per week for 6 hours or more per day during the month prior to enrollment. * Willing to maintain habitual soft CL wear of a minimum of 5 days per week for 6 or more hours per day for the 1 month duration of the study. * Habitual CLs have an acceptable fit (good centration, movement, and coverage Exclusion Criteria: * Any history of acoltremon 0.003% use. * Are currently an overnight CL wearer. * Are currently hard or scleral CL wearers. * Have known systemic health conditions that are known to alter tear film physiology (e.g., primary and secondary Sjögren's syndrome). * Have a history of ocular surgery within the past 12 months. * Have a history of viral eye disease that may confound study results. * Have a history of severe ocular trauma, active ocular infection or inflammation. * Have ever used isotretinoin-derivates (e.g., Accutane). * Are currently taking ocular medications (including topical glaucoma medication) or plan to during the study. * Have had a physical meibomian gland treatment withing 1 month of enrollment (iLux, Lipiflow, Radio Frequency and IPL with manual expressions, microblepharoexfoliation etc.). * Have used a prescription DED medication in the last 1 month. * Unwilling to agree to discontinue artificial tear use the day before enrollment and throughout the study. * Have a condition or in a situation, which in the examiner's opinion, may put the subject at significant risk, may confound the study results, or may significantly interfere with their participation. * Are pregnant or breast feeding.